MGNX - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon.

We will begin the MacroGenics' 2021 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions] At this point, I will turn the call over to Chris James, Vice President of Investor Relations and Corporate Communications of MacroGenics.

Chris James

Thank you, operator. Good afternoon, and welcome to MacroGenics' conference call to discuss our third quarter 2021 financial and operational results.

the not a chance outlining press which available has results, review today's who our is issued on we release under anyone had macrogenics.com. to the these announcement, website For at tab Investors this afternoon

for result XXXX. include purposes to archived like quarterly today's You safe Actual be of with including call via and webcast it XX those is about after various under forward-looking the those to the provision of days that differ Securities filed the beginning statements may completed. conference on may this SEC. these the will from forward-looking future call important would website, Factors alert annual, Company's our materially listeners expectations, factors, discussion Private of that our also the in prospects where section of results hours indicated and statements discussed I Act listen for a will the Litigation Risk approximately reports as X Reform plans current by harbor statements, constitute

date. only forward-looking representing views views be subsequent represent of our relied today our of addition, any any should In upon and statements as as as not

the at While do applicable disclaim law. update forward-looking we the some over by of required Chief MacroGenics. our now Dr. to we call extent Executive even these to President may and views future, And point like if any statement elect the so, statements in Scott to turn to Officer to specifically obligation Canning, change, I'd except

Scott Koenig

programs. to Financial results Karrels, This afternoon, for the financial highlights quarter. provide participating me do call like everyone webcast our will via from But Officer, today. Jim Chris. call so, I key I'd review turn let you, Thank third Chief will before the first conference our who to our clinical welcome I and

Jim Karrels

financial as Thank our highlight ended progress. the as our financial XX, well position you, MacroGenics This quarter for afternoon, XXXX, recent Scott. results reported September which

revenue to $X.X XXXX, total September the from quarter consisting MARGENZA. included $XX.X XX, MacroGenics' $XX.X the XX, for of afternoon, XX, agreements, was revenue this for release the net million Revenue compared collaborative revenue total primarily XXXX, September sales ended XXXX. ended September million of in the for described As quarter million a ended quarter

Selling, flotetuzumab. million the net development to MARGENZA MacroGenics' Our increase XX, ended for XXXX, XXXX. administrative quarter to for launch, compared $XX the for September XXXX, legal and expenses. general the related expenses ended XXXX. trial September $XX.X compared $X.X This related were to research quarter was XX, the million ended labor-related and the primarily This million and for $XX.X XXXX, the costs ended for to $XX.X to ended loss of to quarter September increased XX, were XX, compared ended and million quarter clinical quarter September million support related well to development costs offset related by as to decreased molecules, for and manufacturing development activities costs million related BLA and $XX.X was September was preclinical company's XX, the the as costs XXXX. decreased September loss expenses partially candidates, product margetuximab, XX, and increase a costs research quarter for net clinical

million September marketable equivalents was December of million cash and balance as XX, to compared as XXXX. XXXX, cash, $XXX.X Our XX, $XXX.X securities of

securities advance and that currently us to call assuming addition enable should in collaborations potential collaboration runway, to equivalents our back as in our September and cash, we turn anticipate fund operations anticipated Finally, of XXXX, And our terms now as I'll marketable programs contemplated. XX, cash through the of cash to and Scott. XXXX, payments

Scott Koenig

Jim. you, Thank

ongoing CDXXX finally, the a GMP encouraging important this with to our for IND fighting substance, DART updates recently goal presented September, BX-HX. we and study facility In our from MGDXXX cancer. preliminary pursuit other manufacturing for with let CDX you molecules multiple continued for of in conjugate. an At achievement me of walk that FDA the providing portfolio antibody of And our drug hematological therapeutics CDXXX drug company. the diseases. of October, produce the by MARGENZA application targeting life-changing pleased approved of targeting our AML anti-BX-HX submitted starting to in potential molecules, ESMO backdrop, next-generation With representing on very I MGCXXX, are treatment potentially and towards patients molecule Phase clinical we We our results an progress time the use expressing through clinical the

a a an investigational encouraging deliver the DNA antibody solid designed escalating advanced cohorts. clinical update drug Let prostate tumor enrollment with patients in expressing conjugate continues other payload castration-resistant our metastatic the BX-HX. in patients study September. The as in analysis me of ongoing expansion cytotoxic enrolled tumors and all analysis tumors or I data ESMO X safety MGCXXX cancer focused of at Phase included poster activity discuss cancer duocarmycin to to the in non-small cell with first MGCXXX, lung presented cohorts, on the presentation MacroGenics from MCRPC

XXXX or response, patients X of of the X partial XX% XX unconfirmed or of XX XX% results a and and reduction of demonstrated patients with X responses. greater XX of or XX XX% and XX, or preliminary of was achieved resist PSA of in partial Antitumor patients XX As data August observed MCRPC. a cutoff, including evaluable of activity XX%

XX% to all study the XX measurable results manageable infusions. XX% and events notably, activity and skin expansion remain was of first with toxicity antitumor be presented As responses. or X MGCXXX. the included, X-week continue XX dose most from in imaging of at XX we cohort who hematologic had growing with toxicities encouraged available, reported demonstrated patients non-small patients in data in our to low-grade ESMO, and the expansion fatigue, patients lung ongoing The and of Overall, by for XX pleased their adverse results of disease cell unconfirmed of cancer or preliminary including

physician plans for during sharing next year. development future of MCRPC with we in first forward had quarter MGCXXX multiple researchers, cancer ESMO, to we the Following practicing our prostate look discussions and

breast In and addition, study the enrollment squamous MGCXXX melanoma the carcinoma in neck cancer, triple-negative cell Phase ongoing of cohorts. and in the I head is

on We provide clinical of expect updates study first multiple the half expansion year. next cohorts to in

to with of PD-X-based monotherapy-based one of anticipate studies, addition the study In year. combination candidates MGCXXX half our a next we in product commencing first of

Biopharma, combination investigational negative neck in In our accepted that with are for with of positive. or to of squamous BX-HX this platform. are Fc in molecules the Phase United its we was patients an with a solid and progress enoblituzumab to either study regimen of tumors pembrolizumab our to trial milestone initiate cell the net PD-LX enoblituzumab, retifanlimab head our overexpression tebotelimab enoblituzumab study $X.X IND announced States, in Enrollment initiated patients solid Europe September, in is who which frontline of of in Another with exploiting select Fc-engineered the a continues created triggered in carcinoma across in in optimization tumors In PD-LX II a MacroGenics. and using antibody who partner, I-Mab chemotherapy-free combination payment March, a China, patients Australia. sites million in

molecules. our our with to investigational acute Next, efforts patients DART me market and leukemia CD treat help X discuss AML or bispecific myeloid products to CDXXX x bring to let

in further in clinical study development AML, the updates of continue the flotetuzumab refractory to with XXXX. clinical flotetuzumab to anticipate enroll on and evaluate We single-arm providing patients we

addition, antitumor FDA. MGDXXX by the The recently MGDXXX, an malignancies. an permit is dosing. cytokine IND the activity, DART intermittent x hematologic prolong we cytolytic minimize FDA application half-life or very patients Fc our to to refractory study in CDXXX designed intend incorporates that to In submitted while molecule we next-generation share clearance maintaining pending IND CDX I'm that syndrome, domain application circulating to pleased relapsed to for CDX with with component along a and release

to expect in MGDXXX at data We ASH December. preclinical present

T x the of superior Next bispecific LAG-X with is walk PD-X allows synergistic our cell through molecule. Tebotelimab blocks cells combinations with and of to or up, for and immune has that ligands investigational PD-X let T me in and seen LAG-X other PD-X-based our tumors. reactivation against single assets. Tebotelimab enhancement PD-X DART agents. as of vitro, expressing and binding LAG-X cells Tebotelimab to capacity demonstrated the LAG-X T activation exhausted their you PD-X

monotherapy, in including as We agents. tebotelimab expanded well are combination with in Zia in a China, partner new patients tract niraparib, triple-negative study and gastric currently with as Greater cancer. other Lab, breast combination inhibitor, our Greater PARP as in both China, into evaluating the in of cancer tebotelimab biliary Phase Ib/II indications cancer,

cohort first the in patient cancer endometrial October the In XXXX. Lab in addition, enrolled Zia

targets Next, checkpoint bispecific MGDXXX DART PD-X and our is molecule investigational that CTLA-X.

update on MCRPC with look conducting and of study We microsatellite Phase year. are We next cohorts in dose melanoma. lung non-small providing stable expansion study to an forward cell I cancer, patients colorectal cancer, checkpoint-naive, the a

to registration-enabling studies antibody Let licensed retifanlimab, exploring patients potentially Incyte Incyte. the carcinoma Merkel is retifanlimab, cancer. and me of that investigational next development to cell and MSI-high turn as cancer, lung anti-PD-X monotherapy we endometrial anal cancer, with in

metastatic is the virtual will in for retifanlimab Merkel repair SITC, of At endometrial Incyte the advanced tumor-specific current patients with a in Cancer meeting results XXXX Incyte Society of poster addition, in portfolio. week. molecule evaluating with In immuno-oncology combination other their the present or assets Immunotherapy next mismatch and in expansion X or cohort MSI-high study from recurrent Phase presentations cell patients or in carcinoma, cancer. deficient both study with a clinical

XXXX. I Immunogen. ADAMX is our an X multiple being IMGCXXXX, anticipate under ADC, initial collaboration tumors Under leading co-development not study development, in immunogen will investigational update margetuximab. solid second provide with XX-XX on disclosing clinical in have a our least, and targets advanced Next, from is agreement data which but they indicated they Phase Last a

Part cancers. been GC first-line and XX% inhibitor cancer. XX patients evaluate retifanlimab with junction advanced resistant for combination metastatic in of in or patients valuable X/X or September, clinical gastric gastroesophageal A MAHOGANY agent ESMO At modules results in gastroesophageal as confirmed with gastroesophageal in MAHOGANY Phase combination with in treatment patients XX from investigational advanced an by patients We or X to with gastric a X evaluating achieved study consists or designed Cohort in the responses This of have Phase junction margetuximab without as with review. potential of presented. a were HERX-positive margetuximab margetuximab checkpoint chemotherapy, trial Cohort and MAHOGANY in study the X/X advanced with cancer A of junction of independent

the Cohort exceeded the responses number pembrolizumab. Although confirmed indication a further including with approval A therapy futility decided to the candidates this and company after the given discontinue enrollment other prespecified based priorities, competition combination our and we of of resources have boundary of of in trial accelerated of the factors, evaluation the number on product prioritization for of

which China, company MARGENZA analysis did patients not Also in demonstrate for a with plus overall B. metastatic Antonio in trastuzumab Cohort patients Our present Greater the from Lab, Breast these partner study, for breast survival X Zia the HERX-positive September, at San Phase in Symposium final to cancer. enroll margetuximab SOPHIA statistically significant continues December. chemotherapy advantage to in chemotherapy plus in Cancer the results plan over We announced

indicated analysis metastatic the in in that Zia V with with showed trial anticipates China to in adult population by anti-HERX who in the in patients regard homozygous With one in breast Chinese plus prespecified received trial. primary submitting endpoint The of it treatment in global cancer of HERX-positive chemotherapy pretreated chemotherapy in in efficacy for is with margetuximab was which launched results that Zai of advantage of our commercial a a breast study breast has addition the more Lab homozygous this In combination that HERX-positive tolerability. of in was partner, metastatic for showed advanced met HERX-positive numerical MARGENZA with acceptable breast X cancer, that have In the approximately non-alpha and was numerical patients. of or coordination combination in F the October, favor favor metastatic metastatic safety in with regimens, previously patients disease. CDXXA SOPHIA bridging margetuximab genotyping its the intent-to-treat recall OS cancer its least margetuximab EVERSANA. BLA in cancer and at advantage from seen that trastuzumab population MARGENZA our a mid-March for allocating OS in patients prior consistent XXXX. announced to Lab approved of study year-end treated

option. benefit continue believe patients to therapy another MARGENZA, We cancer marketed may as from

MARGENZA $X.X As the third reported, net from were million sales quarter. in

expectations for the the market, multiple we to Given in including new place HERX-positive taken realities continue breast that modest sales. competitive approvals, cancer have have MARGENZA

to the sales expect year. least has provide product We the been on MARGENZA for guidance a market after at

MARGENZA open Rockville, and continuing now our facility we product another candidates Maryland. represents The in for approval MacroGenics. advancing Finally, be XXXX to pipeline into drug FDA Operator? We We to approval manufacture and innovative manufacturing call of happy supplemental recently BLA U.S. to for MARGENZA substance throughout forward to look build XXXX. momentum, for important received at would GMP our the questions. achievement

Operator

And from of line comes Instructions] [Operator with first Peter Barclays. question the our Lawson

Peter Lawson

melanoma Scott, year? guess, timing on around order just and sense of triple-negative the there? of What's just, I kind next sense prostate of lung the BX-HX, for the any

Scott Koenig

very Thanks Peter. much,

we on the had regard melanoma that. addition, non-small have continue enrollment breast, cell completed completed the enroll, neck, enrollment cohorts. lung prostate castration-resistant not cohort cancer in commented triple-negative ESMO, we in As to -- obviously, and the the to metastatic The in head with of

And to the obviously, and head triple-negative We enroll continue the XXXX. year. to the the melanoma breast neck expect of the and before end into

enrolled. patients to the after follow patients been have want we So obviously, all those

one very the course, encouraged of continued the provide on an updates. the time other at on the And available I've by we'll be at the will and say as to also in conferences lung with, half scientific updates well. the provide studies I X, commented today, year, prostate. the first earlier appropriate progress prostate of of should So additional on certainly as

the key We leaders very are large prostate by in who cancer opinion number have to-date. engaged of encouraged a data

Peter Lawson

kind kind Got first the a then of or from, is half, in meaningful of X indications? to sense of you you. have want And like a what, update it X

Scott Koenig

At around didn't say the greatest this that priority of point, is the the right patients. prostate. I We now number advancing enrolled would

opportunity. And to on like focus therefore, a that the of next obviously set. we'd very stage looking at for significant have data development We

whether For less on have forward before be patients, instance, patients we'll for we've many additional the a required going other of cohorts where decision decision will a registration. make we in make patients enrolled cohort, XX a to final

make we see I until that. can't really data, on So the comments

Peter Lawson

similar data or LAG-X. just question And that? your further of around we data question, around final just Got you. then do just kind When PD-X to see get

Scott Koenig

at remains Peter, as as that we’ve and of we conducting, very again, And publicly year sizable commented a different were the we’ve before, conferences data the X the about trials. amount encouraging. this, we Zia have spoken data from incremental on last provided had ongoing studies data

we right expect that As I they’ll additional is, further that from of now. you taking decisions that would sufficient reported of be indications. can’t Zia is both results. us earlier that data, to various now is is have solid working today, the we’re timing I their in studies right the molecule the parties What us as heard, indications. sense data time tumor amount going these conducting. specific and make speak to on we’re trials on additional And update combination development other when many of conducting with any is My for liquid that engaging tumor about of

on obviously to combination part all lost both or expect So as sight single agent opportunity the right in has the little a provide BX-HX, not portfolio, that the but on now, XXXX. tebotelimab, we potentially be and the given agent a right patient, properly priority updates efforts first of within our highest have now on

Operator

And with our Kaveri comes next from of question Pohlman line the BTIG.

Kaveri Pohlman

affinities? difference question is CDXXX first bit if Fc? is my it molecule us us different on development Is a guess, for strategy about can binding like MGDXXX. there. a insight you the I CDX give flotetuzumab the little or your And some a different tell besides how Maybe epitope

Scott Koenig

to very regard now Larry, x CDX we're the the excited much, specificity. first this call of thank today. which you we're the prospects With platform, XXX about to MGDXXX, very to and welcome applying

will CDX ability slightly preclinical reduce molecule on to vivo. intermittently in that the variants note, have Fc has, questions studies, is around not that particularly to conducted we regard release, With molecule for for it theoretically cytokine off A is, your a a And vitro able us studies, to is relative the Cmax molecules. have affinity, was is what and to the to based that we story. as we the does compared also in As in lot incorporating release. we the have but this has that a cytokine significant whole do it CDX, on to modified flotetuzumab. as specific flotetuzumab are comprehensive so half-life precipitating before, and our specific affinity without what believe you This both allow because the rates this longer an decreased domain, of achieve of give spoken

this X with AML study, could escalation. used So this dose and can if I conventional to advance not major solid With this that flotetuzumab, the But given the think clinically design, be only but be a tumor regard also then to for our X could design forward. do, as of get proposed performs be preclinically, the indications we've CDXXX seen moving other escalation a bearing for as malignancies, dose be fairly dose should well. rapid a indication will specific and a plus we experience applied

Kaveri Pohlman

Got Module it. MAHOGANY study. B And for of

and evaluating And of at XXX sense CTLA-X their in least, melanoma, with well makes combining the disease. large patients IPI cohort Nivo works negative the PD-X think status. cohort? you PD-LX PD-X starting for before Do combination You're a regardless

Scott Koenig

I melanoma. Module So use questions. and of X XX B in were there the think

had study dose for melanoma in Lab. to this So data, Greater being of With being status. with in we right with enrolled irrespective MGDXXX instance, have now Patients regard currently positive to ongoing. in melanoma. study utility Obviously, with and the is the are of Module correct, patients a have PD-LX XXX advanced we very China monotherapy regard B, by the in escalation Zia

study expansion have an there We well. as ongoing

of that melanoma had are address lot portfolio progressed with being our on of prospects of there from a standard current late-stage patients care. So to able

for that address needs could portfolio tuned steps our forward for in potential stay the next in So melanoma. molecules

Operator

Citi. Yigal the from question next with our comes Nochomovitz of line And

Asha Babaric

A. I you any were for on decision A the to Babaric the Yigal. Cohort sorry, discontinue This the module? to on able can is you guess, Module additional Asha I'm MAHOGANY provide Cohort color in And just FDA PD-LX the high think might on curious adding bar be regimen there gastric with speak that chemo benefit to I'm any approval? also for about cancers? if And accelerated you to

Scott Koenig

A. question. decision very to regard very with was you much tough for thank us Module a Asha, for the It

in Given better regimen, than side obviously that also response our chemo-free before, a out chemotherapy. was that that which to with expected approval. patients too to recent us again, hoped profile for to has being believe we dramatically a for rate, the accelerated the a year achieved chemo-free But for caught best bit predefined What response putting certainly in came to meaning time. what and before of that And we we’ve in approval potential not behind patients. XX% should We then regard effect assess ToGA I resources good study. this XXX continuing it discussed what been regimen when surprise particularly the us funds the we market reemphasize, data previously as of little opportunity has small at and may more with use, a we XXX this use asked led here, accelerated result, question, it an the tolerate reported and by pursue probably our is we we a deemed

ongoing discontinued study. We will and from publish data the recently the

the So of margetuximab that sense anti-PD-X use experimentally. you’ll a very this get good and a of good is of Redefault combination

of the FDA. to continue Again, that questions raised best address about have will and did with be was that. engagement contribution how we there So to

the approval of if this that pembrolizumab pathway chemotherapy resources and an regard to was putting to a behind accelerated look PD-LX triple that really positive. combination So chemotherapy, study, at in no With the were lot XXX fact, of more Herceptin combination there you in XX% real molecule. with get the clear patients without

the newly gastric patients cancer cancer are so majority with And of positive. diagnosed, and gastroesophageal PD-LX these

is So of in expectations combination very And tebotelimab the what that perform with marge addition hope or B, of well. able chemotherapy, our the retifanlimab is achieve which being again, to should potentially module would is essentially chemotherapy, we done that be goal.

Operator

Our Leerink. next Jonathan Chang line with of question from the comes SVB

Jonathan Chang

indications what the beyond your First thoughts could prostate for are potential question, MGCXXX latest cancer? on opportunities be what in

Scott Koenig

really Jonathan, since nothing ESMO. Well, changed again, has

we're alternative these point, given been to some be one total we're the different be in know, you too who As as study, that any at out, combination this opportunity also that tumor additional open expressing We've of going even there cohorts, the expansion in a I I also should BX-HX that could combination checkpoint of on as the that And with enoblituzumab these not opportunities. other there. space, vast early which to expansion many indicated our checkpoint reason moving quite will see one no think data X we've of having multiple just our to space. this monotherapy. point responses or types tumors with also or are yet into for molecules. good at to identifying competitors molecules, ones well already solid this is having tumor of of completed point, begin there's MGCXXX, cohorts, shouldn't testing work or in that in the are It's

are the we BX-HX, clinic in opportunities high on now. very in the So ones the

We we preclinically are have that additional also ones developing.

will we be efforts a towards so lot of going forward this putting target. And

Jonathan Chang

my follow-up question You answered the competitor on data. actually

the regimen you thinking that development I'll dose on and are and maybe which steps. next question switch How to to about another forward is with? So MGCXXX, on move

Scott Koenig

Jonathan. question, Excellent

results received on a, to on #X, that the KOLs, As out, we of #X, in have the the and we huge Again, address, groups earlier, engage was from from all and met KOLs have date, as stated to to study to we discuss regimens. commented fronts them. the have profile a feedback safety number I we and dosing the #X, the encouraged ongoing #X, very that interviewed

responsiveness. additional receive correlated expansion the and XX patients of with of for and pharmacokinetics in various the at the looking the at modifications that patients cohort their doses looking they how are we patients before, noted have we As ultimately dose the these

the have finalized, to of reduction or the regard dose the We some has but But dosing have that frequency we very our of the we that. identified are a of the registration clearly populations could regulatory strategy. initial agencies the intent initial we potential additional forward. These year. also we identifying controlled in going patients the XX then get pathway final shortly, will as design, use reducing though, This engage going will end on with before forward. study. decisions about come And been include dosing would decision data the not on not that Again, a fine-tuning the we forward

Operator

And question Miller from of Evercore ISI. the our next comes Jonathan line with

Jonathan Miller

of program moving molecule pushing I that expansions steps sort that even the like gating PD-X trial some not favorite, | competitive path value that like forward Even getting, next LAG-Xs your you But if am earlier on for bispecific. thing. given that I'm waiting what the harder. and development factors forward? year. presented surprised designs commentary I the LAG-X But are are Jonathan. path it we're to for revisit I things indication and second more on would about getting I And gave you're wonder that the know development you call seems on clarity this the in a still

Scott Koenig

Well, John, I the will know. state you are Jonathan, we in ones savored,

our molecule. bispecific don't would So of was specific that that our LAG-X combination a yes, we a interest working many you. obviously on tough of didn't also recognize of other not more we do the PD-X and which of regard x there portfolio, is are in I certainly PD-X prioritization. in in molecules. least number would if this But BX-HX the companies With separate have wealth to on given robust call competitive molecules, choices say terms to your that on CTLA-X here there to some antibodies make have accelerated of we bispecific, the feel landscape, speaking such working reflective be effort couple and second

I looking -- for you liquid have discuss lot and we of point tip competitive here. tumor are we're work, before as solid there Again, the I'd this not indication. we completed going off where well forward a exactly Again, a next out, as to like landscape, tumor very as would going design Given closely a is potentially rather at that do appropriate indication, a steps.

others for consider the of of with Some we utility, context those And what and in of going melanoma in are in study. instance, the that appropriate about should the things shown the a other has diagnostic one some Bristol forward of what is is their things are designing valuable. data the expression LAG-X this through what working is

activity like patient. of molecule. this be please So We the do

data We going expect, earlier, Lab forward additional few indications pointed lot I of Zia the in from a out over as next months.

So I will also appropriate on that what to the molecule think for us in this hone steps help are. next

Jonathan Miller

One that could for if sounded initial smaller of get decisions next year? later it you might for be would about like follow-up. cohorts disclosure expansion what stage the Can expansion your we Earlier on data the decide disclose later not from before call, making cohorts clarify XXX, criteria you increase in you to cohort size studies. any given those multiple

Scott Koenig

Yes.

the study what criteria competitive for we're about ones to the of somebody until and hold best make wary are we what that to going pursuing us I tip close decisions forward. than and specific here. decision. landscape Again, And we sort the any off made very are haven't like when of registration would on, which We rather a

with assurances. that. please to we trying that, set So with to are us patient high regard be said bars very Having on

XX And sometimes, types. that data so of instance, patients, cancer quickly for I'll very cell were the initial there a you non-small which perfect different histological on X was the We presented give lung example.

picking right make we be possibly to you're if type before sure want make forward that decision cancer, pursued. the is what's that decided want the to next step lung tumor going you on So to a

So those are some of the things about we're forward. going thinking

Jonathan Miller

the have a that that pleased hints, dialogues I'm context give at people update to has with KOL forward and had indication the worked the dosing that cancer what first year, profile regimen safety us been indication? of you modifications how as we the that prostate about when earlier the to modifications hear in ASCO. saying the quarter or And from the cohorts, updated you call can follow-up KOLs having in far. little in from next to observed ESMO One thus presentation and after look productive you you're

Scott Koenig

Yes.

is said profile well. the these I to consistent the with that should to further be even dosing think regard safety with mitigate toxicity improve And further what regard effects before, what some here. seem we’ve I’ve working discussed side strategies with which the some of strategies taken very manageable changes of we’ve to

in So stands obviously, now, as what’s on in predict I data future. can’t all all, the going the

very have on where We’re implemented the now. safety stands right what encouraged data we and set

Operator

Tuerkcan comes Silvan Our next question line from JMP Securities. with of the

Silvan Tuerkcan

looking what future do My into comment first a for in quarter. even you MGDXXX, next Or Is the you human question molecule you're maybe if Congrats data about planning on bar both? need ASH the of on that, just your please? other data early from maybe this options or is goes is, MGDXXX? data one Could there could flotetuzumab? you molecule? certain please set? comment around for follow-up the Or And it in

Scott Koenig

very regard provided thank becomes in Silvan, complex, being landscape is are with to you to more the continually more AML, the that patients. and opportunities again, to call. a as And much, welcome opportunities this

to population. primary the achieved very regard identifying would responsive populations that so on flotetuzumab these particularly with with what induction failure strategies, drug, have And again, encouraged be we most to dosing

study conducting As single-arm you know, with this flotetuzumab. we are

theory, and potential regard we'll at We on during forward patient's to the the with the could with that to provide taking patients regard benefits which, we of to profiles. are the convenience moving escalation obviously, interim some robustness side of And data. in while look additional MGXXX, be will effect dose enrollment the with looks that continue

of have the space would -- on I and seeing profile, to initial on we the push then in forward some on the continuing make we'll to say and anticipated XXX address going meets that AML So decisions general. forward hope data space our if flotetuzumab. We to we're in will how XXXX, largest

So we in. more updates will XXXX provide as in data comes

Silvan Tuerkcan

But just molecule seen from studying? think in competitive trial this flotetuzumab side with of CRS profile in that you the effect terms is, the itself, space, to-date. by is Do that we've

Scott Koenig

the the it’s particularly of we’re think competitive other in that induction preclinical it discussions even our meets our of if obviously that through also do based is additional FDA. some expand shared data, that failure, We indications with AML much pursuing could at the point have this criteria populations. which we anticipated opportunities particular to it There not with we are on you primary

it I a great that a have do set AML all to effective than that criteria achieve, has MGDXXX flotetuzumab. yes, again, But be out if more could So, we opportunity. drug much opportunity and even the think meets larger

Operator

Stifel. And our with comes next of Willey question line Stephen the from

Stephen Willey

to formulation the Just dosing with relationships preclinically, then to start have pursuing of up further X seen a that flat And step dose you subcutaneous Phase about I in there have is regimen have a blunt you're terms back not you little guess, thought a dosing all Cmax to the to at or for XXX, escalation in based a mind? exposure off upon you that, dosing strategy you've maybe guys contemplated or bit? going second whether going a

Scott Koenig

quickly fairly in but have has discussed in subcu. there, be immediately, It thought AML it complications typical is certainly expect. to dose we what wary would study. intravenous but So should be as a patients cytokine something we're able we escalation, dosing But little start our has with a given again, on the of the safety here, that in think have going here a probably dosing, regard a certain as been to been our experiences to to something move and based have you release profile the flotetuzumab we discussed and X one going have Yes, reduced regard in internally. up with we to we Phase of highlight terms going obviously out, that better forward. giving in much chemic preclinically shown and not experience the certainly, opportunity current escalation, with opportunity Again, we're dose to

Operator

of comes David next Our from question line with Lebowitz the Morgan Stanley.

Unidentified Analyst

This Avatar for on is David today.

We the question cancer have another opportunity on for margetuximab. gastric

successful MAHOGANY outcome any module? in So you following in the can for just And would provide Module A, benefit a rates? on expectations what Module terms view your of incremental granularity minimum, response B as on results you from at

Scott Koenig

you for very much the thank Avatar, question.

but if obviously, in what Our With rate, certainly expectations combination with regard you at as seen overall require, adequate good, would response study profile preferred to least one XXX XX% good. from response than be the in still And we recall, we pembro. that safety they rate, data that better would that likely was in an the was the meet not or of the had triple that. that PFS exceed combination, don't open them like would have is because rate certainly very things a their to was is

you If XX.X a XX.X was it patients. our that months, months given of recall PFS chemoprevention also MAHOGANY was with smaller was A number that

comparable. quite it's So

their something whatever would going again, look be XXX. to to PFS regard a have overall that would at to potentially exceed with benefit out survival. So what we take that to and that And to for turns ultimately, be look we're

Operator

that, [Operator I'll call remarks. So with for management over Instructions] the turn any closing to back

Scott Koenig

call the the look our forward great have Thanksgiving holiday. in on and that near-term a to programs in updating participating today. you for everyone, hope Thanks, you We

Operator

for concludes This Thank participating. call. today's conference you

now may You disconnect.

MacroGenics (MGNX) 3 Nov 212021 Q3 Earnings call transcript